CytoDyn Announces Settlement with Amarex Clinical Research LLC
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s...
Vaccine
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving...
Richland Aesthetics, Newport Beach’s Luxury Med Spa
Richland Aesthetics in Newport Beach, CA introduces state-of-the-art medspa treatments in a serene, luxurious setting, providing Newport Beach and Newport...
FDA Updates Guidance to Further Empower Companies to Address the Spread of Misinformation
SILVER SPRING, Md., July 8, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is advancing its mission of...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development...
Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia...
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives...
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more...
Rapid Dose Therapeutics Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today...
Moderna Receives Project Award through BARDA’s Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million...
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines...
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than...
Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), is pleased to...
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST Inside information: Orion and MSD Announce Mutual Exercise...
Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for...
Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA)...
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered...
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...